18F-fluoromisonidazole positron emission tomography before treatment is a predictor of radiotherapy outcome and survival prognosis in patients with head and neck squamous cell carcinoma - PubMed (original) (raw)
18F-fluoromisonidazole positron emission tomography before treatment is a predictor of radiotherapy outcome and survival prognosis in patients with head and neck squamous cell carcinoma
Masahiro Kikuchi et al. Ann Nucl Med. 2011 Nov.
Abstract
Objective: To evaluate the usefulness of [(18)F]fluoromisonidazole ([(18)F]FMISO)-positron emission tomography (PET) prior to the treatment of head and neck squamous cell carcinoma.
Methods: Seventeen patients with untreated HNSCC underwent pretreatment [(18)F]FMISO PET. Six of them underwent definitive surgery and the remaining 11 definitive (chemo-)radiotherapy. We evaluated 30 lesions from the 17 patients. SUVmax and tumor-to-muscle ratios (TMR) were measured as hypoxia indicators. Tumors equal to or above the median value were defined as tumor with high uptake of [(18)F]FMISO and those below as tumor with low uptake of [(18)F]FMISO in both indicators. Local control rates with radiotherapy, event-free survival and disease-specific survival (DSS) rates with radiotherapy or operation were compared.
Result: [(18)F]FMISO-PET imaging of 30 lesions resulted in a SUVmax median value of 2.3 and a TMR median value of 1.3. Local control rates with radiotherapy (20-month median follow-up duration) were significantly lower in the tumor group with high uptake of [(18)F]FMISO compared to the tumor group with low uptake of [(18)F]FMISO using either SUVmax or TMR as the hypoxic indicator (P = 0.02 and 0.04, respectively). DSS rate with radiotherapy or operation (21-month median follow-up duration) was significantly lower in the patient group with high uptake of [(18)F]FMISO compared to the patient group with low uptake of [(18)F]FMISO defined by SUVmax (P = 0.04), but was not by TMR (P = 0.57).
Conclusions: Radiotherapy outcome and survival prognosis (radiotherapy or operation) in HNSCC may be predicted by carrying out [(18)F]FMISO PET before treatment.
Similar articles
- High reproducibility of tumor hypoxia evaluated by 18F-fluoromisonidazole PET for head and neck cancer.
Okamoto S, Shiga T, Yasuda K, Ito YM, Magota K, Kasai K, Kuge Y, Shirato H, Tamaki N. Okamoto S, et al. J Nucl Med. 2013 Feb;54(2):201-7. doi: 10.2967/jnumed.112.109330. Epub 2013 Jan 15. J Nucl Med. 2013. PMID: 23321456 - Effect of [(18)F]FMISO stratified dose-escalation on local control in FaDu hSCC in nude mice.
Schütze C, Bergmann R, Brüchner K, Mosch B, Yaromina A, Zips D, Hessel F, Krause M, Thames H, Kotzerke J, Steinbach J, Baumann M, Beuthien-Baumann B. Schütze C, et al. Radiother Oncol. 2014 Apr;111(1):81-7. doi: 10.1016/j.radonc.2014.02.005. Epub 2014 Mar 14. Radiother Oncol. 2014. PMID: 24636842 - The reoxygenation of hypoxia and the reduction of glucose metabolism in head and neck cancer by fractionated radiotherapy with intensity-modulated radiation therapy.
Okamoto S, Shiga T, Yasuda K, Watanabe S, Hirata K, Nishijima KI, Magota K, Kasai K, Onimaru R, Tuchiya K, Kuge Y, Shirato H, Tamaki N. Okamoto S, et al. Eur J Nucl Med Mol Imaging. 2016 Nov;43(12):2147-2154. doi: 10.1007/s00259-016-3431-4. Epub 2016 Jun 1. Eur J Nucl Med Mol Imaging. 2016. PMID: 27251644 Clinical Trial. - Hypoxia PET Tracers in EBRT Dose Planning in Head and Neck Cancer.
Hodolič M, Fettich J, Kairemo K. Hodolič M, et al. Curr Radiopharm. 2015;8(1):32-7. doi: 10.2174/1874471008666150316222400. Curr Radiopharm. 2015. PMID: 25808959 Review. - [Metabolic tailoring in radiotherapy for head and neck cancer].
Servagi-Vernat S, Giraud P. Servagi-Vernat S, et al. Cancer Radiother. 2014 Oct;18(5-6):565-71. doi: 10.1016/j.canrad.2014.05.011. Epub 2014 Aug 30. Cancer Radiother. 2014. PMID: 25179254 Review. French.
Cited by
- PET radiopharmaceuticals for imaging of tumor hypoxia: a review of the evidence.
Lopci E, Grassi I, Chiti A, Nanni C, Cicoria G, Toschi L, Fonti C, Lodi F, Mattioli S, Fanti S. Lopci E, et al. Am J Nucl Med Mol Imaging. 2014 Jun 7;4(4):365-84. eCollection 2014. Am J Nucl Med Mol Imaging. 2014. PMID: 24982822 Free PMC article. Review. - Glioma FMISO PET/MR Imaging Concurrent with Antiangiogenic Therapy: Molecular Imaging as a Clinical Tool in the Burgeoning Era of Personalized Medicine.
Barajas RF, Krohn KA, Link JM, Hawkins RA, Clarke JL, Pampaloni MH, Cha S. Barajas RF, et al. Biomedicines. 2016 Oct 31;4(4):24. doi: 10.3390/biomedicines4040024. Biomedicines. 2016. PMID: 28536391 Free PMC article. - Dynamic contrast-enhanced MR imaging in predicting progression of enhancing lesions persisting after standard treatment in glioblastoma patients: a prospective study.
Yoo RE, Choi SH, Kim TM, Park CK, Park SH, Won JK, Kim IH, Lee ST, Choi HJ, You SH, Kang KM, Yun TJ, Kim JH, Sohn CH. Yoo RE, et al. Eur Radiol. 2017 Aug;27(8):3156-3166. doi: 10.1007/s00330-016-4692-9. Epub 2016 Dec 14. Eur Radiol. 2017. PMID: 27975145 - Ultrasound and Microbubbles Mediated Bleomycin Delivery in Feline Oral Squamous Cell Carcinoma-An In Vivo Veterinary Study.
de Maar JS, Zandvliet MMJM, Veraa S, Tobón Restrepo M, Moonen CTW, Deckers R. de Maar JS, et al. Pharmaceutics. 2023 Apr 6;15(4):1166. doi: 10.3390/pharmaceutics15041166. Pharmaceutics. 2023. PMID: 37111651 Free PMC article. - Correlation between FMISO-PET based hypoxia in the primary tumour and in lymph node metastases in locally advanced HNSCC patients.
Bandurska-Luque A, Löck S, Haase R, Richter C, Zöphel K, Perrin R, Appold S, Krause M, Steinbach J, Kotzerke J, Hofheinz F, Zips D, Baumann M, Troost EGC. Bandurska-Luque A, et al. Clin Transl Radiat Oncol. 2019 Feb 15;15:108-112. doi: 10.1016/j.ctro.2019.02.002. eCollection 2019 Feb. Clin Transl Radiat Oncol. 2019. PMID: 30834349 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical